US Stock MarketDetailed Quotes
SNSE Sensei Biotherapeutics
- 0.500
- -0.013-2.59%
Close Dec 4 16:00 ET
- 0.510
- +0.010+2.00%
Post 16:04 ET
12.58MMarket Cap-420P/E (TTM)
0.534High0.460Low242.54KVolume0.520Open0.513Pre Close118.96KTurnover1.47%Turnover RatioLossP/E (Static)25.15MShares1.94052wk High0.27P/B8.27MFloat Cap0.38452wk Low--Dividend TTM16.55MShs Float26.500Historical High--Div YieldTTM14.42%Amplitude0.384Historical Low0.490Avg Price1Lot Size
Sensei Biotherapeutics Stock Forum
Sign in to post a comment
$Sensei Biotherapeutics (SNSE.US)$ anyone got any insights why? shoed FDA phase 1 approved.
1
$Sensei Biotherapeutics (SNSE.US)$ Sensei Biotherapeutics Inc: Reported Encouraging Clinical Data From Dose Escalation Portion of Its Phase 1/2 Trial of Sns-101
Once Every 3-Week Dosing of Sns-101 Demonstrates Initial Signs of Promising Clinical Activity
Pharmacokinetic and Safety Profile Validate Conditionally Active Approach in Study
Sensei Biotherapeutics Inc: Expects to Report Initial Data From Dose Expansion Cohorts and to Hold an End-of-Phase 1 Meeting With...
Once Every 3-Week Dosing of Sns-101 Demonstrates Initial Signs of Promising Clinical Activity
Pharmacokinetic and Safety Profile Validate Conditionally Active Approach in Study
Sensei Biotherapeutics Inc: Expects to Report Initial Data From Dose Expansion Cohorts and to Hold an End-of-Phase 1 Meeting With...
4
9
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Sensei Biotherapeutics (SNSE.US)$ • There have been no dose limiting toxicities (DLT) observed across both the monotherapy and the combination arms.
• Sensei will present topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.
• Title: Initial result...
• Sensei will present topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.
• Title: Initial result...
2
$Sensei Biotherapeutics (SNSE.US)$ can we push pass 1.9 and go 2 onwards
2
1
Revolutionary Cancer Treatment on the Horizon: How Sensei Biotherapeutics' SNS-101 Could Change the Game.
In the ongoing battle against cancer, groundbreaking research and innovative treatments are the beacons of hope for patients worldwide. One such beacon shines brightly from the laboratories of Sensei Biotherapeutics, Inc., a clinical-stage immuno-oncology company dedicated to the discovery and development of next-gen...
In the ongoing battle against cancer, groundbreaking research and innovative treatments are the beacons of hope for patients worldwide. One such beacon shines brightly from the laboratories of Sensei Biotherapeutics, Inc., a clinical-stage immuno-oncology company dedicated to the discovery and development of next-gen...
$Sensei Biotherapeutics (SNSE.US)$
NEWS
Sensei Biotherapeutics, Inc. (SNSE) announces the publication of a research paper in Nature Communications detailing the development of SNS-101, a pH-sensitive monoclonal antibody targeting VISTA to suppress T-cell activation in cancer patients. The paper highlights the unique mechanism of SNS-101 in mitigating CRS risk and maintaining a favorable safety profile, potentially revolutionizing VISTA-directed immunotherapy.
NEWS
Sensei Biotherapeutics, Inc. (SNSE) announces the publication of a research paper in Nature Communications detailing the development of SNS-101, a pH-sensitive monoclonal antibody targeting VISTA to suppress T-cell activation in cancer patients. The paper highlights the unique mechanism of SNS-101 in mitigating CRS risk and maintaining a favorable safety profile, potentially revolutionizing VISTA-directed immunotherapy.
The appointment of Krebs is viewed as a positive step for Sensei, as it may further the company's capabilities in strategic alliances, pipeline expansion and program development. Her extensive experience could be valuable to the company's growth.
No comment yet
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Jaguar8 OP 151429803 : Not on my radar. Huge float. Needs a huge PR to run. Shorts love huge floats